{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-019328","form_type":"8-K","ticker":"CHRS","cik":"0001512762","company_name":"Coherus Oncology, Inc.","filed_at":"2023-11-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.320871+00:00","generated_at":"2026-06-07T21:26:58.718316+00:00","sec_items":["7.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Coherus sets LOQTORZI price at $8,892.03/vial for NPC treatment","bullets":["FDA approved LOQTORZI (toripalimab-tpzi) on Oct 27 for first-line and later-line metastatic NPC.","Coherus announced wholesale acquisition cost of $8,892.03 per single-use vial on Nov 27.","LOQTORZI is co-administered with cisplatin and gemcitabine in first-line setting.","This pricing establishes commercial launch basis for the PD-1 inhibitor in NPC."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-019328","json":"https://secwatch.observer/filing/0001558370-23-019328.json","markdown":"https://secwatch.observer/filing/0001558370-23-019328.md","text":"https://secwatch.observer/filing/0001558370-23-019328.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1512762/000155837023019328/0001558370-23-019328-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1512762/000155837023019328/chrs-20231127x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T21:26:58.718316+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}